Cardiff Oncology Inc (NASDAQ:CRDF) concluded the trading at $3.81 on Wednesday, November 06 with with a rise of 3.25% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $3.69 and 5Y monthly beta was reading 1.954 with its price kept floating in the range of $3.525 and $3.99 on the day. Considering stock’s 52-week price range provides that CRDF hit a high price of $6.42 and saw its price falling to a low level of $0.94 during that period. Over a period of past 1-month, stock came adding 39.05% in its value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
With its current market valuation of $177.36 million, Cardiff Oncology Inc is set to declare its quarterly results in December. Analysts are in estimates of -0.27 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -1.0 for current year with estimates of that growing to -1.04 in next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of 80k. The average estimate is representing a decrease of -43.30% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of 530k in current fiscal year, which will be 8.60% more from revenue generated by the company last year.
In contrast, when we review CRDF stock’s current outlook then short term indicators are assigning it an average of 50% Buy, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of 50% Buy for it.
According to ratings assigned by 1 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 0 of them are recommending Cardiff Oncology Inc (CRDF) as a Hold, while 1 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the CRDF stock which is currently positioned at 0. It further provides that stock’s current price level is 27.58% away from its 20-day simple moving average and is 41.66% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 78.99 while volatility remained at 13.43% over the past week which changes to 8.58% when measuring it over the past month. Beta is valued at 1.97, while measure of average true range or ATR is currently at 0.27.
Having a second look at Cardiff Oncology Inc (NASDAQ:CRDF) provides that stock’s average daily trading volume for 3 months was 577.78K, while it jumped to 960430 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 44.68 million.
The percentage of outstanding shares held by the insiders is 7.76% while it is 26.24% for the institutional holders. The figures also indicate that as of 2024-10-15, number of stock’s short shares was 7.32 million which implies a short ratio of 13.38. This shows up a 1616.00 of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 6.9 million in the previous month. Addition of 157.43% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
